Corporate Governance

Governance of Daewoong Pharmaceutical

2024

2024 Activities
No. Date Agendas Pass/Fail Participation
9 10/30/2024 1. Resolution on the Appointment of a New Manager
2. Appointment of Compliance Officer
Approved 6/6
8 08/08/2024 1. Stock-based compensation scheme resolution Approved 5/6
7 07/15/2024 1. Payment guarantee regarding corporate loan by Indonesian affiliate company Approved 6/6
6 04/29/2024 Reports Approved 6/6
5 04/18/2024 1. Bank loan and collateral provision (construction investment) Approved 6/6
4 03/28/2024 1. Inauguration of CEO Approved 5/6
3 03/21/2024 1. Resolution on changes to investment (construction investment) Approved 6/6
2 03/08/2024 1. Approval of separate financial statement and consolidated financial statement Approved 6/6
1 02/26/2024 1. Confirmation of general meeting of stockholders and agendas
2. Approve Allotment
3. Approval of corporate bond issuance limit
Approved 5/6

2023

2023 Activities
No. Date Agendas Pass/Fail Participation
5 10/27/2023 1. Investment in another corporation Approved 4/6
4 07/27/2023 1. The establishment of Daweoong Group ESG Committee Approved 6/6
3 05/02/2023 1. Approval of concurrent position of CEO
2. Approval of facility(Nabota) investment
Approved 6/6
2 04/12/2023 1. Designation of Authorized Representative Approved 5/6
1 03/08/2023 1. Approval of separate financial statement and consolidated financial statement
2. Confirmation of general meeting of stockholders and agendas
3. Stock Dispositions
4. Approval of concurrent position of CEO
Approved 5/6

2022

2022 Activities
No. Date Agendas Pass/Fail Participation
6 10/28/2022 Reports Approved 4/6
5 10/07/2022 Cash loan to Employee Stock Ownership Union Approved 5/6
4 07/28/2022 Reports Approved 6/6
3 05/09/2022 Reports Approved 5/6
2 03/08/2022 1. Approval of separate financial statement and consolidated financial statement
2. Confirmation of general meeting of stockholders and agendas
3. Amendment of Board of Directors regulation
4. Approval of EHS (Environment, Safety, Health) plan
Approved 4/5
1 01/03/2022 Inauguration of CEO Approved 4/5

2021

2021 Activities
No. Date Agendas Pass/Fail Participation
6 10/26/2021 Reports Approved 5/5
5 07/07/2021 Issuing of public corporate bonds(15th, KRW 90 Bil. Won) Approved 5/5
4 05/06/2021 Approval of safety & health plan 2021 Approved 3/5
3 03/26/2021 Inauguration of CEO Approved 5/5
2 03/18/2021 Stock Dispositions Approved 2/3
1 03/11/2021 1. Induction of electronic voting
2. Approval of separate financial statement and consolidated financial statement
3. Confirmation of general meeting of stockholders and agendas
Approved 3/3

2020

2020 Activities
No. Date Agendas Pass/Fail Participation
7 10/21/2020 Financing (funding) Approved 3/3
6 07/30/2020 Established internal accounting rules and auditor occupational rules Approved 3/3
5 07/07/2020 Acquired convertible bond rights Approved 2/3
4 05/07/2020 Established the ion-channel platform VITVO and allowed the concurrent position of CEO Approved 3/3
3 03/23/2020 Stock Dispositions Approved 2/3
2 03/05/2020 Approval of separate financial statement and consolidated financial statement Approved 4/4
1 02/27/2020 Confirmation of general meeting of stockholders and agendas Approved 4/4

2019

2019 Activities
No. Date Agendas Pass/Fail Participation
5 10/18/2019 Issuing of corporate bonds Approved 3/4
4 10/18/2019 Approval for issuing of corporate bonds Approved 3/4
3 4/11/2019 Issuing of corporate bonds Approved 3/4
2 3/7/2019 Approval of separate financial statement and consolidated financial statement Approved 3/4
1 3/6/2019 1. Confirmation of general meeting of stockholders and agendas
2. Granting of stock options
3. Investment in Magok District
Approved 4/4

2018

2018 Activities
No. Date Agendas Pass/Fail Participation
4 9/21/2018 1. Granting of stock options
2. Approval of anti-corruption policies
Approved 3/4
3 7/6/2018 1. Issuing of corporate bonds Approved 4/4
2 3/23/2018 1. Inauguration of CEO
2. Change of HQ address
Approved 3/4
1 2/28/2018 1. Confirmation of general meeting of stockholders and agendas
2. Approval of 16th separate financial statement and consolidated financial statement
Approved 1/1